Picture a BD director at a mid-size European biopharma sitting across from a Chinese counterpart in early 2024. She’s expecting the usual dynamic: technology flows west, capital and manufacturing expertise flow east. Instead, the term sheet on the table runs in the opposite direction. A Chinese biotech, flush with domestically validated clinical data, is offering to license a Phase 2 asset into Western markets at a valuation that undercuts every comparable deal she has seen from a San Diego or Cambridge, Massachusetts company in the past three years. She takes it back to her CEO. The CEO calls the head of BD. Nobody has a precedent playbook for this.
That scene, playing out repeatedly across 2023 and 2024, is the signal that the biotech recovery narrative has been getting wrong. The sector has bounced off its floor. Biopharma IPOs climbed to 32 deals in 2024, raising capital above 2023’s 27-deal trough. Venture capital deployment into biopharma reached $26.0 billion across 416 funding rounds in 2024, up from $23.3 billion the prior year. But the shape of the recovery, not its existence, is what determines who survives the next five years. And the shape is deeply uncomfortable for anyone who built their portfolio strategy on assumptions that were still valid in 2019.
The XBI tells the story with brutal clarity.
A Recovery That Doesn’t Feel Like One
After losing 25.87% in 2022, the SPDR S&P Biotech ETF gained just 7.60% in 2023 and 1.00% in 2024, according to Morningstar data. Compare that to the Nasdaq’s performance across the same period, and you have your answer to why biotech capital committees are still nervous. The sector recovered technically. It has not recovered psychologically, financially, or structurally. And those three gaps are creating the real strategic picture that portfolio managers and BD teams need to understand before they make their next move.
The VC data is instructive precisely because of what it hides. The headline number, $26 billion deployed in 2024, sounds like a green light. Underneath it, the number of funding rounds actually fell, from 462 in 2023 to 416. Capital went up. Deals went down. That means the money is concentrating in fewer, larger bets, a pattern that creates a brutal bifurcation: well-networked platforms with strong lead investors are raising mega-rounds while the middle of the market quietly empties out. For any biotech that raised a Series A in 2021 and expected a Series B to follow in 18 months, the arithmetic has become genuinely dangerous. The floor is firmer. The ladder has fewer rungs.
The IPO market confirms it. In 2023, 27 biopharma companies went public, raising a combined $3.54 billion, a number that would have been a single large SPAC deal in 2021. The class of 2024 lagged with a 29% average decline post-listing. Public market investors, still carrying wounds from the 2021 vintage, are repricing risk in ways that private market valuations have not fully absorbed. The bid-ask spread between what founders believe their assets are worth and what the public market will pay for them remains the single most underappreciated friction in the biotech ecosystem right now.
Which is exactly the moment when China walked in with a different offer.
The Competitive Variable Nobody Priced In
Open the Nature Reviews Business Brief citing Stifel’s 2025 Biopharmaceutical Outlook and the data is unambiguous: China-to-West pharma licensing deals surged in 2024, driven by Chinese biotechs that have built genuine clinical validation on assets they now want to monetize globally. The China biotechnology market generated $74.2 billion in revenue in 2023 and is projected to reach $263 billion by 2030, growing at a 19.8% CAGR. That is not an emerging market story. That is a parallel innovation ecosystem that has reached sufficient scale to compete on terms, not just on cost.
The counterintuitive read here is important. The conventional assumption in Western biopharma boardrooms has been that Chinese biotechs compete on manufacturing scale and speed, but lack the regulatory sophistication and scientific differentiation to challenge for best-in-class designations in complex mechanisms. The 2024 licensing surge breaks that assumption. When a Western BD team takes a China-originated asset and structures a deal to bring it into FDA registration trials, they are making an implicit statement: the data is credible, the mechanism is differentiated, and the risk-adjusted economics beat anything available domestically at the same development stage. That is a competitive shift with permanent consequences for how U.S. and European biotechs are valued relative to their clinical-stage peers.
For any mid-cap oncology or immunology company sitting on a Phase 2 asset and expecting to run a competitive partnering process in 2025 or 2026, a Chinese biotech with equivalent data is now bidding against them. The implied royalty rate compression across the next licensing cycle is real, and the large pharma BD teams already know it.
The second structural shift runs parallel to the first, and in some ways makes it more acute.
The Timeline That Changes the Math
Insilico Medicine brought an AI-discovered drug for idiopathic pulmonary fibrosis from target identification to Phase 2 clinical trials in under 30 months, a process that traditionally consumes six to eight years. That compression does not simply mean faster science. It means the commercial window for any given mechanism begins to close faster, and the competitive moat that comes from being first into a target class shrinks proportionally.
A Jefferies research report, drawing on 42 expert call transcripts, found that AI drives cost savings of approximately 40 to 50% in early discovery and regulatory writing stages. That cost reduction is beginning to show up in how deals are structured, not just in how R&D budgets are managed. When the cost to generate a clinical candidate falls by half, the risk premium that a large pharma acquirer assigns to a preclinical asset should fall with it. But current M&A pricing has not fully reflected this. There is still a valuation gap between what AI-native biotechs believe their accelerated timelines are worth and what acquirers are willing to embed in upfront payments versus milestone structures. The negotiation over that gap is the central tension in early-stage BD right now.
As of 2024, no AI-designed drug had received full FDA approval, which gives large pharma’s BD teams a legitimate reason to keep milestone-weighting deals heavily toward late-stage readouts. But the clinical pipeline is filling fast. The first AI-originated approval, whenever it comes, will reprice the entire category overnight, and any company that waited for that signal before building AI-native partnerships will find itself negotiating from behind.
For a CEO reviewing her R&D portfolio today, the practical implication is uncomfortable: the pipeline she built over five years to give her competitive separation in a target class can now be replicated by a well-capitalized AI platform in under three years, or sourced from China at a lower cost basis. Neither threat is hypothetical. Both are in the market.
The BD director who took that Chinese term sheet back to her CEO in early 2024 made the right call. What matters now is what her company does with the asset, because the licensing deal itself is no longer the strategic event. The strategic event is what comes after: the FDA pathway, the launch sequencing, the payer access story in a market where the originating clinical data was generated under a different regulatory system. Those are the questions that the next generation of biotech partnerships will be won or lost on, and very few organizations have built the capabilities to answer them cleanly. The ones that do will not just survive the recovery. They will define what the industry looks like on the other side of it.
References
- Nature Biotechnology — “Biotech’s coming of age”
- BioWorld — “Biopharma IPOs rebound slightly as class of 2024 lags with a 29% average decline”
- BioSpace — “2024’s Top 7 VC Raises in Biotech”
- Morningstar — SPDR S&P Biotech ETF (XBI) Annual Performance Data
- Grand View Research — “China Biotechnology Market Size & Outlook, 2024–2030”
- Generics and Biosimilars Initiative — “China-to-West Pharma Licensing Deals Surge in 2024”
- AI Magic X — “AI Drug Discovery: Insilico Medicine IPF Timeline Data”
- PMC / NLM — “FDA Approval Status of AI-Designed Drug Candidates as of 2024”
- Investing.com — “Jefferies Finds AI Drives Up to 50% Cost Cuts in Drug Development”
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
